Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

Trial Profile

Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2014

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Facial-wrinkles
  • Focus Adverse reactions; Registrational
  • Sponsors Revance Therapeutics
  • Most Recent Events

    • 29 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top